James Spychalski, MD
Family Medicine · Parkersburg, WVNPI 1689630741
Payments from drug & device makers
Across 1,092 payments — averaging $14.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Novo Nordisk$2K
- AstraZeneca$2K
- Lilly USA, LLC$2K
- Boehringer Ingelheim$1K
- Pfizer$1K
- plus $5K from 29 others
What the payments were for
- Food & beverage$16,180100%
- Education$650%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 222 | $3,135 |
| Novo Nordisk | 158 | $1,999 |
| AstraZeneca | 96 | $1,987 |
| Lilly USA, LLC | 105 | $1,515 |
| Boehringer Ingelheim | 103 | $1,494 |
| Pfizer | 98 | $1,260 |
| Johnson & Johnson | 54 | $706 |
| Sanofi-aventis U.S. LLC | 45 | $704 |
| Kowa Pharmaceuticals America, Inc. | 31 | $486 |
| Merck | 36 | $486 |
| Exact Sciences | 21 | $376 |
| Astellas Pharma US Inc | 19 | $298 |
| Novartis | 15 | $221 |
| Bayer | 13 | $216 |
| E.r. Squibb & Sons, L.L.C. | 14 | $211 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $134 |
| GSK | 7 | $124 |
| Corcept Therapeutics | 6 | $111 |
| Amgen | 5 | $83 |
| Dexcom, Inc. | 5 | $80 |
| Xeris Pharmaceuticals, Inc. | 1 | $75 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $63 |
| Daiichi Sankyo Inc. | 3 | $61 |
| Viatris Specialty LLC | 2 | $47 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $47 |
| Biohaven Pharmaceuticals, Inc. | 3 | $45 |
| Verona Pharma, Inc. | 2 | $41 |
| Phathom Pharmaceuticals, Inc. | 1 | $33 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 2 | $31 |
| Supernus Pharmaceuticals, Inc. | 2 | $26 |
| Aimmune Therapeutics, Inc. | 1 | $24 |
| Eisai Inc. | 1 | $14 |
| Phadia US Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,245 in reported general payments places this provider in the 95th percentile of 843 family medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 118 | $190,503 |
| JardianceEmpagliflozin | 123 | $161,285 |
| EliquisApixaban | 178 | $154,020 |
| MounjaroTirzepatide | 78 | $148,691 |
| XareltoRivaroxaban | 63 | $65,353 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 58 | $52,364 |
| EntrestoSacubitril/Valsartan | 42 | $51,718 |
| CreonLipase/Protease/Amylase | 19 | $50,516 |
| TrulicityDulaglutide | 37 | $47,198 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 35 | $46,744 |
| Tresiba Flextouch U-200Insulin Degludec | 42 | $43,739 |
| FarxigaDapagliflozin Propanediol | 38 | $40,343 |
| TradjentaLinagliptin | 49 | $39,425 |
| LinzessLinaclotide | 34 | $28,041 |
| MyrbetriqMirabegron | 30 | $25,218 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Combivent Respimat | $1,494 | $215,241198 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,515 | $195,888115 claims |
| Novo NordiskOzempic | $1,999 | $190,503118 claims |
| PfizerEliquis | $1,260 | $154,020178 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $1,987 | $98,854111 claims |
| AbbVieCreon, Linzess | $3,135 | $78,55753 claims |
| Johnson & JohnsonXarelto | $706 | $65,35363 claims |
| NovartisEntresto | $221 | $51,71842 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $704 | $46,74435 claims |
| Astellas Pharma US IncMyrbetriq | $298 | $25,21830 claims |
| GSKTrelegy Ellipta | $124 | $21,91521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 843 family medicine providers in West Virginia.
Other family medicine in Parkersburg
- Wilbur SineMorgantown$179K
- Dorian WilliamsMorgantown$169K
- Julie DetempleSouth Charleston$129K
- Clemente DiazRichwood$127K
- John CornellHuntington$94K
- Mark CucuzzellaHarpers Ferry$59K
- Courtney PilkertonMorgantown$45K
- Isha WoofterClarksburg$27K
- Dominick WoofterClarksburg$27K
- Ryan RunyonPrinceton$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.